Pamidronate is frequently a therapeutic choice in managing Paget disease of bone, multiple myeloma, hypercalcemia of malignancy, and bone metastases of breast cancer.

Nephrotoxicity is another feared side effect of pamidronate, and careful monitoring of a patientâ€™s renal function by members of the healthcare team is paramount throughout treatment.

The interprofessional team approach to pamidronate therapy can drive patient outcomes positively while limiting potential adverse events. [Level 5]